Now showing items 1692-1711 of 3526

    • An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. 

      Wyszynski, A; Hong, C-C; Lam, K; Michailidou, K; Lytle, C; Yao, S; Zhang, Y; Bolla, MK; Wang, Q; Dennis, J; Hopper, JL; Southey, MC; Schmidt, MK; Broeks, A; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Peto, J; Dos-Santos-Silva, I; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Nordestgaard, BG; González-Neira, A; Benitez, J; Neuhausen, SL; Brenner, H; Dieffenbach, AK; Meindl, A; Schmutzler, RK; Brauch, H; GENICA Network; Nevanlinna, H; Khan, S; Matsuo, K; Ito, H; Dörk, T; Bogdanova, NV; Lindblom, A; Margolin, S; Mannermaa, A; Kosma, V-M; kConFab Investigators; Australian Ovarian Cancer Study Group; Wu, AH; Van Den Berg, D; Lambrechts, D; Wildiers, H; Chang-Claude, J; Rudolph, A; Radice, P; Peterlongo, P; Couch, FJ; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Henderson, BE; Dumont, M; Teo, SH; Wong, TY; Kristensen, V; Zheng, W; Long, J; Winqvist, R; Pylkäs, K; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; García-Closas, M; Figueroa, J; Klevebring, D; Czene, K; Hooning, MJ; van den Ouweland, AMW; Darabi, H; Shu, X-O; Gao, Y-T; Cox, A; Blot, W; Signorello, LB; Shah, M; Kang, D; Choi, J-Y; Hartman, M; Miao, H; Hamann, U; Jakubowska, A; Lubinski, J; Sangrajrang, S; McKay, J; Toland, AE; Yannoukakos, D; Shen, C-Y; Wu, P-E; Swerdlow, A; Orr, N; Simard, J; Pharoah, PDP; Dunning, AM; Chenevix-Trench, G; Hall, P; Bandera, E; Amos, C; Ambrosone, C; Easton, DF; Cole, MD (2016-09)
      Breast cancer is the most diagnosed malignancy and the second leading cause of cancer mortality in females. Previous association studies have identified variants on 2q35 associated with the risk of breast cancer. To identify ...
    • Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. 

      Page, EC; Bancroft, EK; Brook, MN; Assel, M; Hassan Al Battat, M; Thomas, S; Taylor, N; Chamberlain, A; Pope, J; Raghallaigh, HN; Evans, DG; Rothwell, J; Maehle, L; Grindedal, EM; James, P; Mascarenhas, L; McKinley, J; Side, L; Thomas, T; van Asperen, C; Vasen, H; Kiemeney, LA; Ringelberg, J; Jensen, TD; Osther, PJS; Helfand, BT; Genova, E; Oldenburg, RA; Cybulski, C; Wokolorczyk, D; Ong, K-R; Huber, C; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oosterwijk, JC; van Zelst-Stams, W; Cook, J; Rosario, DJ; Domchek, S; Powers, J; Buys, S; O'Toole, K; Ausems, MGEM; Schmutzler, RK; Rhiem, K; Izatt, L; Tripathi, V; Teixeira, MR; Cardoso, M; Foulkes, WD; Aprikian, A; van Randeraad, H; Davidson, R; Longmuir, M; Ruijs, MWG; Helderman van den Enden, ATJM; Adank, M; Williams, R; Andrews, L; Murphy, DG; Halliday, D; Walker, L; Liljegren, A; Carlsson, S; Azzabi, A; Jobson, I; Morton, C; Shackleton, K; Snape, K; Hanson, H; Harris, M; Tischkowitz, M; Taylor, A; Kirk, J; Susman, R; Chen-Shtoyerman, R; Spigelman, A; Pachter, N; Ahmed, M; Ramon Y Cajal, T; Zgajnar, J; Brewer, C; Gadea, N; Brady, AF; van Os, T; Gallagher, D; Johannsson, O; Donaldson, A; Barwell, J; Nicolai, N; Friedman, E; Obeid, E; Greenhalgh, L; Murthy, V; Copakova, L; Saya, S; McGrath, J; Cooke, P; Rønlund, K; Richardson, K; Henderson, A; Teo, SH; Arun, B; Kast, K; Dias, A; Aaronson, NK; Ardern-Jones, A; Bangma, CH; Castro, E; Dearnaley, D; Eccles, DM; Tricker, K; Eyfjord, J; Falconer, A; Foster, C; Gronberg, H; Hamdy, FC; Stefansdottir, V; Khoo, V; Lindeman, GJ; Lubinski, J; Axcrona, K; Mikropoulos, C; Mitra, A; Moynihan, C; Rennert, G; Suri, M; Wilson, P; Dudderidge, T; IMPACT Study Collaborators; Offman, J; Kote-Jarai, Z; Vickers, A; Lilja, H; Eeles, RA (2019-12)
      BACKGROUND:Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 ...
    • Interlaboratory Reproducibility of a Targeted Metabolomics Platform for Analysis of Human Serum and Plasma. 

      Siskos, AP; Jain, P; Römisch-Margl, W; Bennett, M; Achaintre, D; Asad, Y; Marney, L; Richardson, L; Koulman, A; Griffin, JL; Raynaud, F; Scalbert, A; Adamski, J; Prehn, C; Keun, HC (2017-01)
      A critical question facing the field of metabolomics is whether data obtained from different centers can be effectively compared and combined. An important aspect of this is the interlaboratory precision (reproducibility) ...
    • Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: A possible interaction with polymorphisms in the interleukin 1 beta gene 

      Lind, H; Zienolddiny, S; Ryberg, D; Skaug, V; Phillips, DH; Haugen, A (2005)
      Summary Tobacco smoking is the main risk factor for lung cancer. Only 10–15% of smokers develop lung cancer, suggesting that genetic factors are of importance in determining individual susceptibility to the disease. Several ...
    • The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway 

      Andreadi, C; Cheung, L-K; Giblett, S; Patel, B; Jin, H; Mercer, K; Kamata, T; Lee, P; Williams, A; McMahon, M; Marais, R; Pritchard, C (COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, 2012-09-01)
      (L597V)BRAF mutations are acquired somatically in human cancer samples and are frequently coincident with RAS mutations. Germline (L597V)BRAF mutations are also found in several autosomal dominant developmental conditions ...
    • Internal microdosimetry for single cells in radioimmunotherapy of B-cell lymphoma 

      Hindorf, C; Emfietzoglou, D; Linden, O; Kostarelos, K; Strand, SE (MARY ANN LIEBERT INC, 2005-04)
      Patients with B-cell lymphoma may have disease manifestations ranging in size from more than a 1000 cm(3) down to the volume of a single cell. If targeted radionuclide therapy is to become a curative treatment, all individual ...
    • International consensus statement on the peri-operative management of anaemia and iron deficiency 

      Muñoz, M; Acheson, AG; Auerbach, M; Besser, M; Habler, O; Kehlet, H; Liumbruno, GM; Lasocki, S; Meybohm, P; Rao Baikady, R; Richards, T; Shander, A; So-Osman, C; Spahn, DR; Klein, AA (Wiley, 2017-02)
    • International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. 

      Lee, AW; Ng, WT; Pan, JJ; Poh, SS; Ahn, YC; AlHussain, H; Corry, J; Grau, C; Grégoire, V; Harrington, KJ; Hu, CS; Kwong, DL; Langendijk, JA; Le, QT; Lee, NY; Lin, JC; Lu, TX; Mendenhall, WM; O'Sullivan, B; Ozyar, E; Peters, LJ; Rosenthal, DI; Soong, YL; Tao, Y; Yom, SS; Wee, JT (2018-01)
      PURPOSE:Target delineation in nasopharyngeal carcinoma (NPC) often proves challenging because of the notoriously narrow therapeutic margin. High doses are needed to achieve optimal levels of tumour control, and dosimetric ...
    • International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. 

      Terpos, E; Morgan, G; Dimopoulos, MA; Drake, MT; Lentzsch, S; Raje, N; Sezer, O; García-Sanz, R; Shimizu, K; Turesson, I; Reiman, T; Jurczyszyn, A; Merlini, G; Spencer, A; Leleu, X; Cavo, M; Munshi, N; Rajkumar, SV; Durie, BGM; Roodman, GD (2013-06)
      The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease.An interdisciplinary panel of clinical experts on MM and myeloma ...
    • The International Penile Advanced Cancer Trial (InPACT): Rationale and Current Status 

      Canter, DJ; Nicholson, S; Watkin, N; Hall, E; Pettaway, C (Elsevier BV, 2019-06)
    • Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma. 

      Lai, AYT; Riddell, A; Barwick, T; Boyd, K; Rockall, A; Kaiser, M; Koh, D-M; Saffar, H; Yusuf, S; Messiou, C
      OBJECTIVES:Whole-body MRI (WB-MRI) is recommended by the International Myeloma Working Group for all patients with asymptomatic myeloma and solitary plasmacytoma and by the UK NICE guidance for all patients with suspected ...
    • Interplay between base excision repair protein XRCC1 and ALDH2 predicts overall survival in lung and liver cancer patients. 

      Chen, X; Legrand, AJ; Cunniffe, S; Hume, S; Poletto, M; Vaz, B; Ramadan, K; Yao, D; Dianov, GL (2018-10)
      BACKGROUND:To deliver efficacious personalised cancer treatment, it is essential to characterise the cellular metabolism as well as the genetic stability of individual tumours. In this study, we describe a new axis between ...
    • Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. 

      Lorente, D; Ravi, P; Mehra, N; Pezaro, C; Omlin, A; Gilman, A; Miranda, M; Rescigno, P; Kolinsky, M; Porta, N; Bianchini, D; Tunariu, N; Perez, R; Mateo, J; Payne, H; Terstappen, L; IJzerman, M; Hall, E; de Bono, J (2018-03)
      BACKGROUND:Evaluation of responses to treatment for metastatic castration-resistant prostate cancer (mCRPC) remains challenging. Consensus criteria based on prostate-specific antigen (PSA) and clinical and radiologic ...
    • Interstitial Cells of Cajal in Deep Esophageal Leiomyoma. 

      Hallin, M; Mudan, S; Thway, K (2017-02)
      Gastrointestinal stromal tumors (GISTs) are potentially aggressive mesenchymal neoplasms with spindle cell, epithelioid, or mixed morphology. They typically express CD117, DOG1, and CD34 and can be diffusely and strongly ...
    • Intraclonal diversity in a Sezary syndrome with a differential response to 2-deoxycoformycin of the two lymphoma cell populations 

      Granjo, E; Lima, M; Lopes, JM; Cunha, N; Teixeira, MD; Santos, F; Candeias, J; Resende, C; Santos, AH; Balanzategui, A; Orfao, A; Matutes, E (BLACKWELL PUBLISHING LTD, 2002-12)
      We report a case of Sezary syndrome with two abnormal CD4(+) T-cell populations detected in the peripheral blood by flow cytometry immunophenotyping and DNA cell content, suggesting a biclonal T-cell lymphoproliferative ...
    • The Intracranial Distribution of Gliomas in Relation to Exposure From Mobile Phones: Analyses From the INTERPHONE Study. 

      Grell, K; Frederiksen, K; Schüz, J; Cardis, E; Armstrong, B; Siemiatycki, J; Krewski, DR; McBride, ML; Johansen, C; Auvinen, A; Hours, M; Blettner, M; Sadetzki, S; Lagorio, S; Yamaguchi, N; Woodward, A; Tynes, T; Feychting, M; Fleming, SJ; Swerdlow, AJ; Andersen, PK (2016-12)
      When investigating the association between brain tumors and use of mobile telephones, accurate data on tumor position are essential, due to the highly localized absorption of energy in the human brain from the radio-frequency ...
    • Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions. 

      Fiche, M; Scabia, V; Aouad, P; Battista, L; Treboux, A; Stravodimou, A; Zaman, K; RLS; Dormoy, V; Ayyanan, A; Sflomos, G; Brisken, C (2019-03)
      Estrogen receptor α-positive (ER-positive) or 'luminal' breast cancers were notoriously difficult to establish as patient-derived xenografts (PDXs). We and others recently demonstrated that the microenvironment is critical ...
    • Intragenic ERBB2 kinase mutations in tumours 

      Cooper, C; Stratton, M (2004-09)